# Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Unlocking Potential with 107.87% Upside

- Link: https://www.directorstalkinterviews.com/recursion-pharmaceuticals-inc-rxrx-stock-analysis-unlocking-potential-with-107-87-upside/4121246110
- Published: 2026-03-24T11:27:06+00:00
- Author: Madison Wilson

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), a dynamic player in the biotechnology
sector, has been turning heads with its ambitious approach to drug discovery. While
the current stock price sits at $3.23, a significant deviation from its 52-week 
high of $6.79, the company offers an intriguing potential upside of 107.87%, according
to analyst ratings.

Founded in 2013 and headquartered in Salt Lake City, Utah, Recursion is not your
average biotechnology firm. With a distinctive focus on integrating cutting-edge
technology across biology, chemistry, and data science, the company is transforming
the way drugs are discovered and developed. Its pipeline includes promising candidates
like REC-4881, REC-617, REC-1245, and REC-3565, all of which are in various stages
of clinical trials targeting conditions ranging from familial adenomatous polyposis
to advanced solid tumors and B-cell malignancies.

Despite its innovative approach, Recursion currently faces financial challenges 
typical of clinical-stage biotech companies. The firm reported a negative EPS of-
1.44 and a free cash flow of -$208.5 million. With a return on equity of -59.54%,
the company is operating at a substantial loss while it invests heavily in its research
and development efforts. These figures are reflected in its valuation metrics, with
a forward P/E ratio of -3.80 indicating expected losses in the near term.

However, what might seem like a risky venture is balanced by the company’s strategic
collaborations with industry giants such as Roche & Genentech, Sanofi, Bayer AG,
Tempus, and Takeda Pharmaceutical Company Limited. These partnerships not only provide
financial backing but also lend credibility to Recursion’s innovative methodologies.

From a technical standpoint, the stock’s 50-day and 200-day moving averages are 
$3.87 and $4.78, respectively, suggesting the stock is currently trading below its
recent trends. The RSI (14) is at 40.25, pointing towards a potential undervaluation,
while the MACD and signal line are closely aligned, indicating a neutral momentum.

Investor sentiment, as reflected in analyst ratings, is cautiously optimistic. With
three buy ratings and five hold ratings, the consensus suggests a wait-and-see approach.
The target price range of $3.00 to $11.00 encapsulates the volatile nature of biotech
investments, yet the average target of $6.71 underscores a significant growth potential.

For investors with a higher risk tolerance and an interest in innovative biotechnologies,
Recursion Pharmaceuticals presents an opportunity to participate in a potentially
groundbreaking company. The firm’s commitment to leveraging technology for drug 
discovery, combined with its strategic partnerships, positions it uniquely within
the healthcare landscape.

As always, investors should consider the inherent risks associated with investing
in clinical-stage biotech firms, including regulatory hurdles and the uncertain 
timeline to profitability. However, for those willing to navigate these challenges,
Recursion Pharmaceuticals offers a compelling story of potential growth and innovation
in the biotech space.

Share on: